Yes, pharma-specialist AI visibility firms exist. AEO Dose is our own practice, and this article explains how to tell real specialists apart from generic AEO vendors by two observable things: whether the audit question set is built from pharma buyer journeys, and whether it tests all five major AI platforms. The criteria are grounded in observable methodology.

Disclosure: this article is published by AEO Dose, which provides pharma AI visibility and AEO readiness audits. The evaluation criteria below are drawn from how we structure our own audit work. The ownership relationship is real and worth naming so you can weigh the criteria with that context. The criteria apply whether you engage us or another firm.

Why this question comes up and what the buyer is really asking

The buyer asking this is a pharma marketing lead who has already accepted that buyers query ChatGPT and Perplexity before they fill out a contact form, and now wants to find someone competent to act on it. You are not looking for a lecture on why AI visibility matters. You are looking for a way to separate a firm that understands your context from one that will run a SaaS playbook against your excipient catalog.

That is the real question underneath the phrasing. "Any recommendations" is shorthand for "how do I avoid paying for generic work dressed up in pharma language." Most AEO services are built for SaaS or ecommerce, where the buyer journey is short and the vocabulary is consumer-facing. Pharma is neither. The evaluation framework below is designed so you can test a vendor's fit before you commit budget.

What AI visibility optimization specifically involves for pharma

For a pharma business, AI visibility optimization means engineering how your company appears when a buyer asks an AI assistant to recommend or compare suppliers. It is not keyword ranking in blue links. It is whether ChatGPT names your CDMO when a formulator asks for solid dose contract manufacturers with a specific capability, and whether Perplexity cites your site when a procurement lead asks for excipient suppliers with a given regulatory profile.

Concretely, the work covers three overlapping concerns inside the broader audit frame. Discovery: does any AI assistant surface your company at all for the questions your buyers actually ask. Accuracy: when it does surface you, does it describe your API portfolio, GMP context, or DMF status correctly. Comparison: when a buyer asks the assistant to compare you against alternatives, how do you fare. These concerns sit alongside, not instead of, the five buyer journey themes covered later (discovery, evaluation, product and capability, commercial, support), which structure the audit's question set. A pharma specialist treats the concerns as distinct problems because a buyer evaluating a nutraceutical formulation partner moves through them differently than a buyer sourcing an active ingredient.

Where generic AEO vendors fall short in pharma contexts

Generic AEO vendors fall short in pharma contexts because their question sets are not built from pharma buyer journeys, and the question set shapes the entire audit. A vendor who runs the same template used for a B2B software client will ask the AI assistants generic commercial questions and miss the specific paths a pharma buyer takes.

I will push back on this directly: domain fluency is not a nice-to-have you can skip by hiring a strong generalist. A generalist does not know that an API buyer and a CDMO buyer ask fundamentally different questions, or that "quality" means something auditable and specific in a GMP context rather than a marketing adjective. When pharma buyer journeys are not reflected in the question set, the audit measures the wrong thing accurately. You get a clean report about queries your buyers never type. The gap is not technique. It is that the vendor does not know what to test, and AEO skill does not substitute for knowing the questions a formulator, a procurement officer, or a regulatory lead would actually ask.

What a pharma-specialized audit should actually test

A pharma-specialized audit should test real buyer questions across all five major AI platforms and across the full set of buyer journey themes, not a keyword list. The methodology is a deliverable you can ask to see before engaging.

At AEO Dose our methodology tests across five platforms (ChatGPT, Gemini, Perplexity, Claude, and Grok) and five buyer journey themes: discovery, evaluation, product and capability, commercial, and support. The platform coverage matters because a buyer using Perplexity gets a different answer than one using Claude, and your visibility can be strong on one and absent on another. The journey themes matter because a discovery question ("who makes this excipient") and a capability question ("which CDMO can handle this formulation at this scale") are distinct queries with distinct answers. A specialist builds the question set from those journeys. A generalist builds it from a keyword tool. When you are learning how to evaluate an AEO vendor's audit methodology, ask to see the exact questions the firm would run for your business.

Qualifications and background that matter for pharma AEO work

Qualifications that matter for pharma AEO work include demonstrable pharma domain fluency and AEO technique, both of which belong in the set rather than one standing above the other. Domain fluency determines whether the firm can design the right questions. AEO technique determines whether it can act on the findings. Neither alone is sufficient.

My own background is the example I can speak to honestly: a B.Pharma degree and more than 12 years in pharma ERP implementation and Computer System Validation. That is not a credential I am waving; it is the reason I know what a DMF reference signals to a buyer and why a formulator cares about a specific excipient grade. You do not need a vendor with my exact history. You need a vendor who can show that someone on the team understands the regulatory and commercial context your buyers operate in. The mechanism is simple: a firm that cannot explain the difference between an API buyer journey and a nutraceutical brand's journey cannot design an audit that reflects either. Domain fluency and AEO technique are both members of the qualification set, and you are checking that both are present.

Questions to ask a prospective pharma AI visibility firm

Ask the firm to show you the actual questions it would run against the AI platforms for your specific business. That answer reveals pharma fluency in a way marketing copy cannot. If the questions are generic commercial prompts with your company name inserted, you have your answer.

Here is a testable list to put in front of any prospective vendor:

  • Which AI platforms do you test, and can you show me a sample question set built for a business like mine?
  • How do you decide which buyer journey themes to cover for an API manufacturer versus a CDMO versus an excipient supplier?
  • Who on your team understands GMP, DMF, and regulatory context, and what is that background?
  • What does your optimization cycle look like after the audit, and how do you measure whether anything changed?
  • What do you not promise? A firm that guarantees AI rankings is telling you it does not understand how the platforms work.

For more detail on structuring this conversation, the broader Finding AI Visibility Services cluster covers vendor-screening questions in depth. The goal is to keep every answer testable against the firm's own deliverables rather than its marketing.

What to expect from Free Check versus Full Audit engagements

A Free Check is a low-commitment snapshot of whether and how you currently appear, while a Full Audit is the structured, multi-platform, multi-journey assessment that drives an optimization plan. Understanding the difference keeps your expectations honest.

A Free AI Visibility Check shows you a first read: a sample of questions run against the platforms so you can see where you stand without a budget commitment. Our response-time commitment on that is 1-2 business days. A Full Audit is the complete methodology: the full question set across all five platforms and all five journey themes, with findings you can act on. After the audit, the working cycle is Audit, Optimize, Build Authority, Measure, Repeat. That loop matters because AI visibility is not a one-time fix. Platforms change their answers, competitors publish, and your own content ages. If you want a first read on where your company currently stands across the five platforms, that is the right entry point.

Get Your Free AI Visibility Check

Request Free Check

Frequently asked questions

What does AI visibility optimization specifically involve for a pharma business?

It involves engineering how your company appears when a buyer asks an AI assistant to recommend or compare suppliers. For pharma that spans three concerns: discovery (does any assistant surface you for the questions your buyers ask), accuracy (does it describe your API portfolio, GMP context, or DMF status correctly), and comparison (how you fare when a buyer asks the assistant to compare you against alternatives). It is distinct from traditional keyword ranking.

Why do generic AEO or SEO agencies struggle with pharma supplier visibility?

Because their audit question sets are built from keyword tools and SaaS or ecommerce templates, not from pharma buyer journeys. When those journeys are not reflected in the questions, the audit accurately measures queries your buyers never type. A generalist does not know that an API buyer and a CDMO buyer ask fundamentally different questions, so the findings describe the wrong conversations. The gap is domain knowledge about what to test, not AEO technique.

What should a pharma-specific AI visibility audit actually test?

Real buyer questions across all five major AI platforms (ChatGPT, Gemini, Perplexity, Claude, Grok) and across the buyer journey themes relevant to your business: discovery, evaluation, product and capability, commercial, and support. Platform coverage matters because visibility can be strong on one assistant and absent on another. Journey coverage matters because a discovery question and a capability question are distinct queries with distinct answers that require separate assessment.

What qualifications should a pharma AEO specialist have?

Demonstrable pharma domain fluency and AEO technique, both as members of the qualification set. Domain fluency determines whether the firm can design the right questions for an API manufacturer, a CDMO, an excipient supplier, or a nutraceutical brand. AEO technique determines whether it can act on the findings. You are checking that both are present. A firm that cannot explain how buyer journeys differ across pharma segments cannot build an audit that reflects them.

How do I evaluate whether a vendor understands pharma buyer journeys?

Ask to see the actual questions the firm would run against the AI platforms for your specific business. If the questions are generic commercial prompts with your company name inserted, the vendor does not understand your journeys. If the questions reflect how a formulator, procurement lead, or regulatory contact would actually phrase a search, including correct use of terms like DMF and GMP context, that is evidence of fluency you can inspect before committing budget.

What should I expect to see in a Free AI Visibility Check versus a Full Audit?

A Free Check is a low-commitment snapshot: a sample of questions run across the platforms so you can see where you currently stand, with a 1-2 business day response commitment. A Full Audit is the complete methodology across all five platforms and all five journey themes, producing findings you can act on. The audit feeds an ongoing cycle of Audit, Optimize, Build Authority, Measure, Repeat, because AI visibility shifts as platforms and competitors change.

What questions should I ask a prospective pharma AEO vendor before engaging?

Ask which platforms they test and to see a sample question set for a business like yours. Ask how they adapt journey themes across API manufacturers, CDMOs, and excipient suppliers. Ask who on the team understands GMP and DMF context. Ask what their optimization cycle looks like after the audit and how they measure change. Finally, ask what they do not promise: any firm guaranteeing AI rankings is signaling it does not understand how the platforms behave.